Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776905 | 0.91 | PTGDR (0.42) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL5777080 | 0.85 | FFAR1 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5772697 | 0.84 | TBXA2R (0.37) | PTGDRTBXA2RPTGER2GRIN2DGRIN3B | |
| SCHEMBL6731677 | 0.81 | GRIN2D (0.35) | PTGDRTBXA2RGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5776746 | 0.81 | GRIN2D (0.41) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL5778024 | 0.81 | GRIN2D (0.41) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL5779249 | 0.80 | TBXA2R (0.38) | PTGDRTBXA2RGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5835723 | 0.80 | GRIN2D (0.35) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL5774989 | 0.80 | GRIN2D (0.36) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL5775908 | 0.79 | PTGDR (0.44) | PTGDRTBXA2RPTGER3PTGER2PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | PTGDR 1/4885TBXA2R 22/4885PTGER3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.